ArticleCancer management and research2026
Clinicopathological Spectrum and Survival in Esophageal Neuroendocrine Carcinoma and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms: A 74-Patient Cohort.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary esophageal neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are rare malignancies with a poor prognosis. Data on clinicopathological features and survival outcomes in Central China are still limited. Methods: We retrospectively analyzed 74 patients with pathologically confirmed untreated primary esophageal NEC/MiNEN between January 2014 and June 2024. Neuroendocrine and non-neuroendocrine components were evaluated using immunohistochemical staining. The primary outcome was overall survival (OS), which was analyzed using the Kaplan-Meier method and Cox regression. Results: Among 74 patients with pathologically confirmed primary esophageal NEC/MiNEN, 95.9% had irregular masses with surface erosion or ulcers. 56 patients had small-cell NEC, of whom 16 had adenocarcinoma/squamous cell carcinoma. Eighteen patients had large-cell NEC, including 12 patients with adenocarcinoma/squamous cell carcinoma. Immunohistochemistry showed high positivity for CD56 (98.6%), synaptophysin (Syn, 95.8%), and insulinoma-associated protein 1 (INSM1, 88.5%), but lower for chromogranin A (CgA, 56.9%). Survival analysis showed that there was a significant difference in OS between patients with limited disease (LD, limited to the primary site with regional lymph nodes) and those with extensive disease (ED, with distant metastasis) (58 months vs 9.0 months, Conclusion: This study confirms that disease stage (LD vs ED) is one of the most important prognostic determinants of esophageal NEC/MiNEN, and organ and lymph node metastases are independent predictors of poor survival. The findings of this study contribute to improving the predictive efficacy of the prognosis of patients with NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.